Commercial Antibodies: The Good, Bad, and Really Ugly
Commercial Antibodies: The Good, Bad, and Really Ugly
复制标题
DOI：
10.1369/jhc.2008.952820
复制
发表时间：
2009-01-01
影响因子：
3.2
通讯作者：
Couchman, John R.
中科院分区：
文献类型：
--
作者：
Couchman, John R.
商业上可获得的抗体的范围越来越大。也许因此，质量控制并不总是它所能和应该的。研究人员必须意识到潜在的陷阱，并采取措施确保每种抗体的特异性与广告宣传的一样。此外，公司应向研究者提供有关抗原和抗体的必要信息，包括参考文献，以便纳入适当的质控品。（组织化学细胞化学杂志57：7-8，2009）
The range of antibodies available commercially grows ever larger. Perhaps as a consequence, quality control is not always what it could and should be. Investigators must be aware of potential pitfalls and take steps to assure themselves that the specificity of each antibody is as advertised. Additionally, companies should provide the necessary information about the antigen and antibody to investigators, including references, so that the appropriate controls can be included. (J Histochem Cytochem 57:7-8, 2009)